{"DataElement":{"publicId":"2180446","version":"1","preferredName":"Lymphoma Diagnosis Hematopoietic Type","preferredDefinition":"the diagnosis of lymphoma based on clinical and pathologic data following guidelines from the World Health Organization (2001) with additional values from intergroup clinical trials.","longName":"LYMPHOMA_DX_HEMP_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014631","version":"1","preferredName":"Lymphoma Diagnosis","preferredDefinition":"information related to the diagnosis of lymphoma.","longName":"LYMPHOMA_DX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177031","version":"1","preferredName":"Lymphoma","preferredDefinition":"A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003","longName":"Lymphoma","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A90-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177541","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"Diagnosis","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-51C6-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC006559-2B08-3C96-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180445","version":"1","preferredName":"Lymphoma Diagnosis Hematopoietic Type","preferredDefinition":"information regarding diagnosis type of lymphoma.","longName":"LYMPHOMA_DX_HEMP_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"125","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Precursor B lymphoblastic leukemia/lymphoma","valueDescription":"PRECURSOR B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)","ValueMeaning":{"publicId":"2559851","version":"1","preferredName":"PRECURSOR B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)","longName":"2559851v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8936","definition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6D8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AE1-4E5D-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Chronic lymphocytic leukemia/small lymphocytic lymphoma","valueDescription":"CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA","ValueMeaning":{"publicId":"2558494","version":"1","preferredName":"CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA","longName":"2558494v1.00","preferredDefinition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","conceptCode":"C27911","definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B18B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AE4-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphoplasmacytic lymphoma","valueDescription":"LYMPHOPLASMACYTIC LYMPHOMA (WALDENSTROM MACROGLOBULINEMIA)","ValueMeaning":{"publicId":"2559133","version":"1","preferredName":"LYMPHOPLASMACYTIC LYMPHOMA (WALDENSTROM MACROGLOBULINEMIA)","longName":"2559133v1.00","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B40A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AE6-4E5D-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Splenic marginal zone lymphoma","valueDescription":"SPLENIC MARGINAL ZONE LYMPHOMA","ValueMeaning":{"publicId":"2560093","version":"1","preferredName":"SPLENIC MARGINAL ZONE LYMPHOMA","longName":"2560093v1.00","preferredDefinition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Marginal Zone Lymphoma","conceptCode":"C4663","definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AE8-4E5D-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","valueDescription":"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUSOSA-ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)","ValueMeaning":{"publicId":"2558767","version":"1","preferredName":"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUSOSA-ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)","longName":"2558767v1.00","preferredDefinition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B29C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AEB-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nodal marginal zone B-cell lymphoma","valueDescription":"NODAL MARGINAL ZONE B-CELL LYMPHOMA","ValueMeaning":{"publicId":"2559556","version":"1","preferredName":"NODAL MARGINAL ZONE B-CELL LYMPHOMA","longName":"2559556v1.00","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B19-4E63-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma not further classifiable","valueDescription":"Follicular lymphoma not further classifiable","ValueMeaning":{"publicId":"2568127","version":"1","preferredName":"Follicular lymphoma not further classifiable","longName":"2568127","preferredDefinition":"Follicular lymphoma not further classifiable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D72C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B1C-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma - grade I","valueDescription":"Follicular lymphoma grade I","ValueMeaning":{"publicId":"2568128","version":"1","preferredName":"Follicular lymphoma grade I","longName":"2568128","preferredDefinition":"Follicular lymphoma grade I","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D72D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B20-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma - grade II","valueDescription":"Follicular lymphoma grade II","ValueMeaning":{"publicId":"2568129","version":"1","preferredName":"Follicular lymphoma grade II","longName":"2568129","preferredDefinition":"Follicular lymphoma grade II","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D72E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B24-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma - grade III","valueDescription":"Follicular lymphoma grade III","ValueMeaning":{"publicId":"2568130","version":"1","preferredName":"Follicular lymphoma grade III","longName":"2568130","preferredDefinition":"Follicular lymphoma grade III","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D72F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B28-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma - grade IIIa","valueDescription":"Follicular lymphoma grade IIIa","ValueMeaning":{"publicId":"2568131","version":"1","preferredName":"Follicular lymphoma grade IIIa","longName":"2568131","preferredDefinition":"Follicular lymphoma grade IIIa","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D730-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E79022-C93C-4E9F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Follicular lymphoma - grade IIIb","valueDescription":"Follicular lymphoma grade IIIb","ValueMeaning":{"publicId":"2568132","version":"1","preferredName":"Follicular lymphoma grade IIIb","longName":"2568132","preferredDefinition":"Follicular lymphoma grade IIIb","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D731-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E79022-C940-4E9F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mantle cell lymphoma","valueDescription":"MANTLE CELL LYMPHOMA","ValueMeaning":{"publicId":"2559149","version":"1","preferredName":"MANTLE CELL LYMPHOMA","longName":"2559149v1.00","preferredDefinition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B41A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E79022-C943-4E9F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma not further classifiable","valueDescription":"Diffuse large B-cell lymphoma not further classifiable","ValueMeaning":{"publicId":"2568133","version":"1","preferredName":"Diffuse large B-cell lymphoma not further classifiable","longName":"2568133","preferredDefinition":"Diffuse large B-cell lymphoma not further classifiable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D732-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E79022-C946-4E9F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mediastinal (thymic) large B-cell lymphoma","valueDescription":"MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA","ValueMeaning":{"publicId":"2559159","version":"1","preferredName":"MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA","longName":"2559159v1.00","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B424-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E79022-C94A-4E9F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Primary effusion lymphoma","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2559886","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2559886","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B2B-4E63-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Intravascular large B-cell lymphoma","valueDescription":"Intravascular large B-cell lymphoma","ValueMeaning":{"publicId":"2568134","version":"1","preferredName":"Intravascular large B-cell lymphoma","longName":"2568134","preferredDefinition":"Intravascular large B-cell lymphoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravascular Large B-Cell Lymphoma","conceptCode":"C4342","definition":"A rare extranodal B-cell non-Hodgkin lymphoma, characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.  This is an extremely aggressive lymphoma which responds poorly to chemotherapy.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D733-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B2E-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Burkitt lymphoma/leukemia","valueDescription":"BURKITT LYMPHOMA/LEUKEMIA","ValueMeaning":{"publicId":"2558345","version":"1","preferredName":"BURKITT LYMPHOMA/LEUKEMIA","longName":"2558345v1.00","preferredDefinition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Leukemia","conceptCode":"C7400","definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B31-4E63-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Burkitt-like lymphoma","valueDescription":"Burkitt-like lymphoma","ValueMeaning":{"publicId":"2568135","version":"1","preferredName":"Burkitt-like lymphoma","longName":"2568135","preferredDefinition":"Burkitt-like lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B34-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Composite B-cell","valueDescription":"Composite B-cell","ValueMeaning":{"publicId":"2568136","version":"1","preferredName":"Composite B-cell","longName":"2568136","preferredDefinition":"Composite B-cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D735-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7D067-2B38-4E63-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Unclassifiable B-cell","valueDescription":"Unclassifiable B-cell","ValueMeaning":{"publicId":"2568137","version":"1","preferredName":"Unclassifiable B-cell","longName":"2568137","preferredDefinition":"Unclassifiable B-cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D736-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E9173D-9937-4E5F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Precursor T lymphoblastic leukemia/lymphoma","valueDescription":"PRECURSOR T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)","ValueMeaning":{"publicId":"2559852","version":"1","preferredName":"PRECURSOR T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (PRECURSOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA)","longName":"2559852v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8694","definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E9173D-993A-4E5F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Blastic NK-cell lymphoma","valueDescription":"BLASTIC NK-CELL LYMPHOMA","ValueMeaning":{"publicId":"2558307","version":"1","preferredName":"BLASTIC NK-CELL LYMPHOMA","longName":"2558307v1.00","preferredDefinition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","conceptCode":"C7203","definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B0D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E9173D-993C-4E5F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"T-cell prolymphocytic leukemia","valueDescription":"T-CELL PROLYMPHOCYTIC LEUKEMIA","ValueMeaning":{"publicId":"2560145","version":"1","preferredName":"T-CELL PROLYMPHOCYTIC LEUKEMIA","longName":"2560145v1.00","preferredDefinition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Prolymphocytic Leukemia","conceptCode":"C4752","definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E9173D-993E-4E5F-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"T-cell large granular lymphocytic leukemia","valueDescription":"T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA","ValueMeaning":{"publicId":"2560144","version":"1","preferredName":"T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA","longName":"2560144v1.00","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7FD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E9173D-9941-4E5F-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Aggressive NK-cell leukemia","valueDescription":"Aggressive NK-Cell Leukemia","ValueMeaning":{"publicId":"2568138","version":"1","preferredName":"Aggressive NK-Cell Leukemia","longName":"2568138","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D737-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA43-4E34-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Adult T-cell leukemia/lymphoma","valueDescription":"ADULT T-CELL LEUKEMIA/LYMPHOMA","ValueMeaning":{"publicId":"2558193","version":"1","preferredName":"ADULT T-CELL LEUKEMIA/LYMPHOMA","longName":"2558193v1.00","preferredDefinition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B05E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA46-4E34-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Extranodal NK/T cell lymphoma nasal type","valueDescription":"Extranodal NK/T cell lymphoma nasal type","ValueMeaning":{"publicId":"2568139","version":"1","preferredName":"Extranodal NK/T cell lymphoma nasal type","longName":"2568139","preferredDefinition":"Extranodal NK/T cell lymphoma nasal type","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D738-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA49-4E34-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Enteropathy-type T-cell lymphoma","valueDescription":"ENTEROPATHY-TYPE T-CELL LYMPHOMA","ValueMeaning":{"publicId":"2558725","version":"1","preferredName":"ENTEROPATHY-TYPE T-CELL LYMPHOMA","longName":"2558725v1.00","preferredDefinition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteropathy-Associated T-Cell Lymphoma","conceptCode":"C4737","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B272-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA4C-4E34-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Hepatosplenic T-cell lymphoma","valueDescription":"HEPATOSPLENIC T-CELL LYMPHOMA","ValueMeaning":{"publicId":"2558871","version":"1","preferredName":"HEPATOSPLENIC T-CELL LYMPHOMA","longName":"2558871v1.00","preferredDefinition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatosplenic T-Cell Lymphoma","conceptCode":"C8459","definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B304-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA4E-4E34-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Subcutaneous panniculitis-like T-cell lymphoma","valueDescription":"Subcutaneous Panniculitis-Like T-Cell ","ValueMeaning":{"publicId":"2560116","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell ","longName":"2560116","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78351-7C42-4E6E-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mycosis fungoides","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"2559297","version":"1","preferredName":"Mycosis Fungoides","longName":"2559297","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B4AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78351-7C44-4E6E-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Sezary syndrome","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78351-7C46-4E6E-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Peripheral T-cell lymphoma unspecified","valueDescription":"Peripheral T-cell lymphoma unspecified","ValueMeaning":{"publicId":"2568141","version":"1","preferredName":"Peripheral T-cell lymphoma unspecified","longName":"2568141","preferredDefinition":"Peripheral T-cell lymphoma unspecified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D73A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78351-7C49-4E6E-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Angioimmunoblastic T-cell lymphoma","valueDescription":"Angioimmunoblastic T-Cell Lymphoma","ValueMeaning":{"publicId":"2558224","version":"1","preferredName":"Angioimmunoblastic T-Cell Lymphoma","longName":"2558224","preferredDefinition":"A mature T-cell non-Hodgkin lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes and extranodal sites.  The clinical course is typically aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B07D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78351-7C4C-4E6E-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Anaplastic large cell lymphoma - primary systemic","valueDescription":"Anaplastic large cell lymphoma - primary systemic","ValueMeaning":{"publicId":"2568143","version":"1","preferredName":"Anaplastic large cell lymphoma - primary systemic","longName":"2568143","preferredDefinition":"Anaplastic large cell lymphoma - primary systemic","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D73C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E934BB-EF11-53D6-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Anaplastic large cell lymphoma - primary cutaneous","valueDescription":"Anaplastic large cell lymphoma - primary cutaneous","ValueMeaning":{"publicId":"2568144","version":"1","preferredName":"Anaplastic large cell lymphoma - primary cutaneous","longName":"2568144","preferredDefinition":"Anaplastic large cell lymphoma - primary cutaneous","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D73D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E934BB-EF15-53D6-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphomatoid papulosis","valueDescription":"LYMPHOMATOID PAPULOSIS","ValueMeaning":{"publicId":"2559132","version":"1","preferredName":"LYMPHOMATOID PAPULOSIS","longName":"2559132v1.00","preferredDefinition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Papulosis","conceptCode":"C3721","definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B409-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E934BB-EF18-53D6-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Unclassifiable CD30-positive cutaneous lymphoproliferative disorder","valueDescription":"Unclassifiable CD30-positive cutaneous lymphoproliferative disorder","ValueMeaning":{"publicId":"2568145","version":"1","preferredName":"Unclassifiable CD30-positive cutaneous lymphoproliferative disorder","longName":"2568145","preferredDefinition":"Unclassifiable CD30-positive cutaneous lymphoproliferative disorder","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D73E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E934BB-EF1B-53D6-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Composite T-cell","valueDescription":"Composite T-cell","ValueMeaning":{"publicId":"2568147","version":"1","preferredName":"Composite T-cell","longName":"2568147","preferredDefinition":"Composite T-cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D740-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E934BB-EF1F-53D6-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Unclassifiable T-cell","valueDescription":"Unclassifiable T-cell","ValueMeaning":{"publicId":"2568148","version":"1","preferredName":"Unclassifiable T-cell","longName":"2568148","preferredDefinition":"Unclassifiable T-cell","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D741-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AEE-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nodular lymphocyte predominant Hodgkin lymphoma","valueDescription":"NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA","ValueMeaning":{"publicId":"2559559","version":"1","preferredName":"NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA","longName":"2559559v1.00","preferredDefinition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","conceptCode":"C7258","definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AF1-4E5D-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Composite Hodgkin lymphoma","valueDescription":"Composite Hodgkin lymphoma","ValueMeaning":{"publicId":"2568149","version":"1","preferredName":"Composite Hodgkin lymphoma","longName":"2568149","preferredDefinition":"Composite Hodgkin lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D742-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AF4-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Nodular sclerosis Classical Hodgkin lymphoma","valueDescription":"NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA","ValueMeaning":{"publicId":"2559561","version":"1","preferredName":"NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA","longName":"2559561v1.00","preferredDefinition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Sclerosis Classic Hodgkin Lymphoma","conceptCode":"C3518","definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AF8-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphocyte-rich Classical Hodgkin lymphoma","valueDescription":"LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA","ValueMeaning":{"publicId":"2559128","version":"1","preferredName":"LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA","longName":"2559128v1.00","preferredDefinition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","conceptCode":"C6913","definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B405-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E78786-5AFB-4E5D-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Mixed cellularity Classical Hodgkin lymphoma","valueDescription":"MIXED CELLULARITY CLASSICAL HODGKIN LYMPHOMA","ValueMeaning":{"publicId":"2559253","version":"1","preferredName":"MIXED CELLULARITY CLASSICAL HODGKIN LYMPHOMA","longName":"2559253v1.00","preferredDefinition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cellularity Classic Hodgkin Lymphoma","conceptCode":"C3517","definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B482-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA57-4E34-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphocyte-depleted Classical Hodgkin lymphoma","valueDescription":"LYMPHOCYTE-DEPLETED CLASSICAL HODGKIN LYMPHOMA","ValueMeaning":{"publicId":"2559127","version":"1","preferredName":"LYMPHOCYTE-DEPLETED CLASSICAL HODGKIN LYMPHOMA","longName":"2559127v1.00","preferredDefinition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","conceptCode":"C9283","definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B404-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA5A-4E34-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Classical Hodgkin lymphoma not further classifiable","valueDescription":"Classical Hodgkin lymphoma not further classifiable","ValueMeaning":{"publicId":"2568150","version":"1","preferredName":"Classical Hodgkin lymphoma not further classifiable","longName":"2568150","preferredDefinition":"Classical Hodgkin lymphoma not further classifiable","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D743-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA5D-4E34-E034-0003BA12F5E7","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1E7855C-AA60-4E34-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207971","version":"1","preferredName":"Hematopoietic Type","preferredDefinition":"Pertaining to or related to the formation of blood cells.:Type; a subdivision of a particular kind of thing.","longName":"C13324:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic","conceptCode":"C13324","definition":"Pertaining to or related to the formation of blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3714-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1E7B46F-0B3F-4E59-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"LYMPHOMA_DX_HEMP_TP","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Hematopoietic Diagnosis","type":"Preferred Question Text","description":"Hematopoietic Diagnosis","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"WHO Diagnosis","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D1E792EC-DA8E-4D1C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"FORMBUILDER","dateModified":"2014-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}